News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Sina Haftchenary

Articles by Sina Haftchenary

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH, FASCO,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD

April 27th 2023

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

ByHope S. Rugo, MD,Joyce O'Shaughnessy, MD,Komal Jhaveri,Sara M. Tolaney, MD, MPH,Fatima Cardoso,Aditya Bardia, MD, MPH, FASCO,Purnima Pathak,Sina Haftchenary,Peter A. Fasching

April 26th 2023

Latest Updated Articles

Trending on CancerNetwork

From Conference to Practice: Top 5 Takeaways From EHA 2026

58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative

57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers

ASCO 2026: Key Insights In Renal Cell Carcinoma, Merkel Cell Carcinoma, and Chronic Myeloid Leukemia

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma